Kairos Therapeutics, Centre for Drug Research and Development cancer news

Centre for Drug Research and Development’s (CDRD) commercialization vehicle, CDRD Ventures Inc., spun off Kairos to develop next-generation antibody-drug conjugate (ADC) therapeutics for cancer. CDRD Ventures granted Kairos an exclusive license to toxin and linker platform technology developed by CDRD. Kairos will also license the technology to potential partners. Kairos named John Babcook, VP of biologics at CDRD, as president and CSO of Kairos. ...